Apollo Endosurgery Inc. (NASDAQ:APEN) saw an upside of 3.18% to $8.75 after adding $0.27 on Wednesday. The 5-day average trading volume is 226,573 shares of the company’s common stock. It has gained $9.63 in the past week. An average of 170,078 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 165,531.
APEN’s 1-month performance is -13.03% or -$1.05 on its low of $8.15 reached on 10/13/21. The company’s shares have touched a 52-week low of $1.61 and high of $10.04, with the stock’s rally to the 52-week high happening on 09/13/21. YTD, APEN has achieved 149.41% or $5.30. However, the current price is down -12.85%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Aug 20, 54 days have gone by since the last insider trading activity for Apollo Endosurgery Inc. (APEN). McKhann Chas (President and CEO) most recently sold 21,148 shares at $7.74 per share on Aug 20. This transaction cost the insider $163,686. President and CEO, McKhann Chas, sold 21,148 shares at a price of $7.89 on Aug 19. Then, on Aug 18, President and CEO McKhann Chas sold 21,156 shares at a price of $8.21 per share. This transaction amounted to $173,691.
Apollo Endosurgery Inc. (APEN) has a trailing price-to-earnings (P/E) ratio of 26.30 for the broader industry and 32.18 for the sector.APEN stock has a beta of 2.18. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 4.25 while the price-to-book (PB) in the most recent quarter is 84.80.
Apollo Endosurgery Inc.’s quick ratio for the period ended June 29 was 3.20, with the current ratio over the same period at 3.90 meaning that APEN stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 20.33, while the total debt to equity was 20.33. In terms of profitability, the gross margin trailing 12 months is 54.90%. The trailing 12-month EBITDA margin is -28.69% while for the period ending June 29; Apollo Endosurgery Inc.’s operating margin was -19.40%. The firm’s gross profit as reported stood at $22.24 million against revenue of $42.05 million.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected APEN to announce -$0.2 per share in earnings in its latest quarter, but it posted -$0.11, representing a 45.00% surprise. EBITDA for the quarter stood at more than -$4.29 million. APEN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 71.7 million, with total debt at $57.85 million. Shareholders hold equity totaling $28.7 million
Let’s look briefly at Apollo Endosurgery Inc. (APEN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 40.53% to suggest the stock is trending Neutral, with historical volatility in this time period at 63.35%.
The stock’s 5-day moving average is $8.99, reflecting a -5.43% or -$0.50 change from its current price. APEN is currently trading -7.35% above its 20-day SMA, +23.76% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +2.11% and +143.02% respectively.
Stochastic %K and %D was 21.52% and 31.29% and the average true range (ATR) pointed at 0.61. The RSI (14) points at 44.07%, while the 14-day stochastic is at 29.57% with the period’s ATR at 0.59. The stock’s 9-day MACD Oscillator is pointing at -0.33 and -0.42 on the 14-day charts.
In the most recent analyst report for Apollo Endosurgery Inc. (NASDAQ: APEN), Stephens launched coverage with an Overweight rating. Analysts offering their rating for APEN stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate APEN as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 4 have offered a “buy” rating.
What is APEN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $14.00 and a high of $15.00, with their median price target at $14.00. Looking at these predictions, the average price target given by analysts is for Apollo Endosurgery Inc. (APEN) stock is $14.25.